Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Apply
Tarlatamab & ZL-1310
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step